At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 3 enrolled
Drug / intervention
Vonoprazandrug
Likely dose
Vonoprazan 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation (VISTAEXE)
In Brief
A Phase 4 clinical trial evaluating Vonoprazan for Reflux Esophagitis. Completed, enrolled 3 participants across 6 sites.
Detailed Summary
The purpose of this study is to exploratorily evaluate the effect of vonoprazan 20 mg on sleep disturbance of patients with reflux esophagitis, who have heartburn and/or regurgitation and ≥ 6.0 in the Pittsburgh Sleep Quality Index (PSQI) global score despite the maintenance treatment with PPI other than vonoprazan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsReflux Esophagitis
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartAug 2017
Primary CompletionDec 2017
TodayJul 2026
First PostedApr 17, 2017
Enrollment StartAug 2, 2017
Primary CompletionDec 20, 2017
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.2 years ago
Interventions
Vonoprazandrug
Vonoprazan 20 mg